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A B S T R A C T
Methylprednisolone is a synthetic glucocorticoid. In our report, the authors proposed a sen-
sitive and selective liquid chromatography/tandem mass spectrometry (LC–MS/MS) assay
for the determination of methylprednisolone applying budesonide as internal standard. Liquid–
liquid extraction (LLE) having tert–butyl methyl ether (TBME) have been employed to extract
methylprednisolone from the plasma samples. Immediately after reconstitution, the samples
were chromatographed on a C18 column using an isocratic mobile phase composed of 10 mM
ammonium formate buffer and acetonitrile (35:65, v/v). A flow rate of 1.00 ml/min was used
to elute the analyte form the column. Analysis was carried out with an API–4000 LC–MS/
MS instrument operated in multiple reaction-monitoring (MRM) mode.The linearity has been
proven within the concentration range of 10.1–804 ng/ml in plasma samples. The preci-
sion (%CV) and accuracy results in five validation batches across five concentration levels
were well within the acceptance limits. The drug was stable under different conditions. The
particular assay has been proficiently put on pharmacokinetic study in healthy male subjects.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Synthetic glucocorticoids are frequently prescribed for a broad
spectrum of diseases such as allergic, inflammatory and au-
toimmune disorders due to their well-known anti-inflammatory
and immunosuppressive properties [1]. Methylprednisolone
(Fig. 1) is a methylated derivative of prednisolone, belonging
to the group of glucocorticoid or corticosteroid drug. The drug
has potent anti-inflammatory activity [2] and is used to treat
conditions such as arthritis, severe allergic reactions, blood dis-
orders, eye conditions and immune system disorders. It
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decreases the immune system’s response to various diseases
to reduce symptoms such as swelling, pain, and allergic-type
reactions. About 77% of methylprednisolone bound to plasma
proteins in humans. The mean elimination half-life ranges is
in the range of 1.8 to 5.2 h.
As per the literature, a lot of LC–MS methods are reported
for the determination of methylprednisolone in a variety of bio-
logical samples like human plasma [3,4], tissue samples [5–7],
human urine [8,9], pig fat [10], bovine milk samples [11,12] and
rat plasma [13]. Of all the methods reported earlier, only two
procedures can be compared with the present work. Re-
cently, Hu et al. [3] reported an LC–MS/MS method for the
determination of methylprednisolone in human plasma using
multi-step solid phase extraction (SPE) technique for the sample
preparation. Initially, sample pretreatment was performed by
protein precipitation (PP) and then processed by online SPE tech-
nique. Another method is reported by Difrancesco et al. [4] for
the determination of methylprednisolone along with other glu-
cocorticoids and immunosuppressive drugs. This method
involves intricacy like gradient elution, typical mobile phase
consisting of two or more buffers with the pH adjustment,
requiring more sample volume (>500 μl) and longer chromato-
graphic run time (>5 min) which are not advantageous if
intended for routine drug analysis of pharmacokinetic/
bioequivalence studies. The rest of the analytical methods
reported so far were not suitable for routine drug analysis.
To study the pharmacokinetics, tolerability and safety of
newer formulations, we need to have a suitable analytical assay
for its identification along with quantification. Nowadays, sen-
sitive and rapid analytical techniques such as LC–MS are most
widely used in bio-analytical applications. The current paper
details a simple, rapid and selective liquid chromatography-
electrospray ionization tandem mass spectrometry (LC–MS/
MS) assay method for the determination of methylprednisolone
in human plasma using budesonide (Fig. 1), as an internal stan-
dard (IS). The projected LC–MS/MS method is developed with
the aim to quantify the methylprednisolone concentrations for
a pharmacokinetic and bioequivalence studies. The following
are the advantages of the proposed method over those re-
ported earlier: (1) Because of the use of less plasma volume
(100 μl), the volume of the sample to be collected per time point
from an individual during the study is reduced significantly.
This allows inclusion of additional points. (2) Employing a single
step liquid–liquid extraction procedure minimizes the chances
of errors, saves considerable time and simplifies the sample
preparation procedure. (3) Greater sensitivity is achieved even
with low plasma volumes and the method is well suited for
pharmacokinetic analysis. (4) The rapid sample turnaround time
of 2.8 min makes it an attractive procedure in high-throughput
bioanalysis of methylprednisolone in human plasma. (5) The
proposed method was successfully applied to quantify the real
time plasma sample concentrations obtained from pharma-
cokinetic study. Additionally, for the first time, assay
reproducibility is demonstrated through incurred sample re-
analysis (ISR).
2. Materials and methods
2.1. Chemicals and reagents
The reference sample of methylprednisolone (98.9%) was pur-
chased from Vivan Life Sciences Limited (Mumbai, India),
whereas budesonide was obtained from Aarti Industries Limited
(Mumbai, India). HPLC grade methanol and acetonitrile were
procured from J.T. Baker (Phillipsburg, NJ, USA). Ammonium
acetate was of analytical grade and was obtained from Merck
Ltd (Mumbai, India). LC–MS grade water was used for the analy-
sis and was prepared at our laboratory using Milli Q water
purification (Millipore, Bangalore, India). Six lots of blank plasma
containing K2 EDTA as an anticoagulant were purchased from
Deccan’s Pathological Lab’s (Hyderabad, India).
2.2. LC–MS/MS instrument and conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Kromasil 100–5 C18, 100 × 4.6 mm, 5 μm (Make: AkzoNobel, Pune,
India), a binary LC–20AD prominence pump, an auto sampler
(SIL-HTc) and a solvent degasser (DGU-20A3) was used for the
study. Aliquot of 10 μl of the processed samples were in-
jected into the column, which was kept at (30 ± 2 °C). An isocratic
mobile phase consisting of a mixture of 10 mM ammonium
formate buffer and acetonitrile (35:65, v/v) was used to sepa-
rate the analyte from the endogenous components and
delivered at a flow rate of 1.0 ml/min with splitter (50:50) into
the electrospray ionization chamber of the mass spectrom-
eter. Mass spectrometric detection was carried out using AB
Sciex API-4000 (Foster City, CA, USA) triple quadrupole mass
spectrometer equipped with a Turboionspray™ in positive ion
mode was used for the quantification of analyte. The source
dependent parameters namely the nebulizer gas (GS1), aux-
iliary gas (GS2), curtain gas and collision gas were set at 45,
40, 20, and 7 psi, respectively. The source voltage was set at
Fig. 1 – Chemical structures (with fragmentation patch) of
methylprednisolone and budesonide (IS).
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5500 V with interface temperature 500 °C. The various com-
pound dependent potentials viz. declustering potential (DP),
collision energy (CE), collision cell exit potential (CXP) and en-
trance potential (EP) were set at 97, 31, 14, 10 V for
methylprednisolone and 80, 20, 10, 10 V for the IS. Multiple-
reaction monitoring mode (MRM) was employed for the
detection by monitoring the transition pairs of m/z 375.2 pre-
cursor ion to the m/z 161.1 for methylprednisolone and m/z 431.3
precursor ion to the m/z 323.3 product ion for the IS. Quadru-
poles resolution was set on unit. Dwell time per transaction
was set at 200 ms. Analyst software™ (version 1.4.2) was used
for the data acquisition.
2.3. Preparation of spiked plasma samples
Methylprednisolone stock solution was prepared in metha-
nol at concentration of 1 mg/ml, whereas further dilutions
(working solutions) of methylprednisolone were prepared in
a mixture of acetonitrile and water (50:50, v/v; diluent). Two
separate stock solutions were prepared and used for the prepa-
ration of calibration standards and quality control samples. A
1 mg/ml concentration of budesonide was also prepared in
methanol and the working concentration (500 ng/ml) was pre-
pared in the same diluent.
Calibration samples and quality control samples were pre-
pared in K2 EDTA human plasma as a bulk. Calibration
standards were prepared at nine concentration levels of 10.1,
20.2, 40.4, 80.8, 162, 323, 482, 643 and 804 ng/ml. Similarly, quality
control (QC) samples at concentrations of 10.1 (lower limit of
quantitation quality control, LLOQ QC), 30.2 (low quality control,
LQC), 88.9 (medium quality control, MQC1), 404 (MQC2) and
709 ng/ml (high quality control, HQC). All the plasma samples
were stored at −70 ± 10 °C.
2.4. Sample extraction protocol
All of the frozen plasma samples have been thawed and equili-
brated at room temperature just before spiking. An aliquot of
100 μl of human plasma sample was spiked with 20 μl of
budesonide dilution (500 ng/ml). After vortexing for 15 s, a 3 ml
of tert–butyl methyl ether was added using Dispensette Organic
(Brand GmbH, Wertheim, Germany). The sample was shaken
for 10 min using a reciprocating shaker and then centrifuged
for 4 min at 4200 rpm on Megafuse 3SR (Heraeus, Germany).
The clear organic layer (2 ml) was transferred to a 5 ml glass
test tube and evaporated at 45 °C under a gentle stream of ni-
trogen. The dried extract was reconstituted with 500 μl of the
mobile phase and a 10 μl aliquot of it was injected into the LC–
MS/MS system.
2.5. Method validation parameters
A complete method validation of methylprednisolone in human
plasma was carried out as per US FDA [14] and EMEA [15] guide-
lines.The validation parameters determined were carryover test,
selectivity, sensitivity, matrix effect, linearity, precision and ac-
curacy, recovery, dilution integrity, long run evaluation,
ruggedness and various stability studies.
The selectivity of the method was assessed in six differ-
ent sources of plasma, of which, four were normal K2 EDTA
plasma and one each of lipemic and helolyzed plasma. Poten-
tial interference from the over-the-counter drugs (paracetamol,
nicotine, pantoprazole, ibuprofen, caffeine, diphenhydr-
amine, dicyclomine and pseudoephedrine) were also evaluated.
Carryover test ended up being conducted to demonstrate any
carryover associated with analyte as well as the IS actuality,
which may be revealed throughout following runs. The carry-
over test samples were injected in the following sequence i.e.
blank plasma sample → six samples of LLOQ → blank plasma
sample → ULOQ sample → blank plasma samples. Sensitivity
was determined by analyzing six replicates of plasma samples
spiked with the lowest level of the calibration curve concen-
trations (LLOQ). Matrix effect, expressed as IS normalized matrix
factor (MF) was assessed by comparing the mean area re-
sponse of post-extraction spiked samples with mean area of
aqueous samples (neat samples) prepared in mobile phase so-
lutions at LQC and HQC levels. The overall precision of the
matrix factor was expressed as coefficient of variation (CV).
Matrix factor
Mean peak area ratio in
the presence of matri
=
x ions
Mean peak area ratio in
the absence of matrix ions
Matrix effect was also evaluated with six different lots of
K2 EDTA plasma. Three replicate samples of each of LQC and
HQC were prepared from different lots of plasma (36 QC
samples in total). The linearity of the proposed method was
determined by analysis of five standard calibration curves (CC)
containing nine non-zero concentrations along with one blank
plasma sample and one zero standard (blank sample with the
IS). Each CC was analyzed individually by least square weighted
(1/χ2) linear regression. Intra-day precision and accuracy results
were determined using six replicates of LLOQ QC, LQC, MQC–
1, MQC–2, and HQC samples analyzed on the same day. Inter-
day precision and accuracy were measured by analyzing five
different analytical batches on three consecutive days. Extrac-
tion recoveries of analyte were determined at LQC, MQC–2, and
HQC by comparing the peak area of extracted analyte sample
with the peak area of non-extracted standard (neat samples).
Similarly, recovery of IS was determined at a concentration of
500 ng/ml. Upper concentration (ULOQ) limit was extended by
conducting the dilution integrity experiment. Six replicates each
at a concentration of about 1.60 times of the uppermost cali-
bration standard were diluted two- and four-fold with blank
plasma.The diluted samples were processed and analyzed using
un-diluted calibration curve standards. Long run evaluation was
carried out to assess the integrity of the samples analyzed in
a long run during study sample analysis. A total of 195 samples
were analyzed in a single run. The method ruggedness veri-
fied by analyzing one precision and accuracy batch on different
column of the same make (different batch no.) using differ-
ent set of reagents processed by different analyst.
The stock solution stability at room temperature and at
2–8 °C in refrigerator was performed by comparing the area re-
sponse stability samples with the response of the sample
prepared from fresh stock solution. The solutions were con-
sidered stable if the deviation within ±10% form nominal value.
Bench top stability at room temperature (15 h), auto-sampler
stability for 65 h, wet extract stability for 55 h and reinjection
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stability for 37 h, freeze–thaw stability (4 cycles) were per-
formed at LQC and HQC levels using six replicates at each level.
Likewise, the long term stability of spiked plasma samples
stored at −70 ± 10 °C and at −20 ± 5 °C for 56 days was also
studied at both the QC levels. The stability samples were pro-
cessed and quantified against freshly spiked calibration curve
standards along with freshly spiked QC samples. Samples were
considered to be stable if assay values were within the ac-
ceptable limits of accuracy (±15% SD) and precision (≤15% RSD).
2.6. Pharmacokinetic study design
A pharmacokinetic study of methylprednisolone was con-
ducted in healthy South Indian male subjects (n = 6). All the
volunteers provided written informed consent and the proto-
col was approved by the local Independent Ethics Committee.
A single dose of methylprednisolone tablet (32 mg) was ad-
ministered orally to all volunteers and blood samples were
collected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3,
3.25, 3.50, 4, 4.5, 5, 6, 8, 10, 12, 16 and 24 h post-dose. An aliquot
of 5 ml blood was collected at each time point in K2 EDTA
vacutainer tubes. Additionally, a predose sample was col-
lected to check the possible interferences from the plasma.The
collected samples were centrifuged to obtain the plasma and
stored at −70 ± 10 °C. Plasma samples were spiked with the IS
and processed along with QC samples at four concentra-
tions. Pharmacokinetic parameters of methylprednisolone were
calculated using WinNonlin (Version 5.2) software package. Sta-
bility of the study samples were established by incurred sample
reanalysis (ISR). For ISR two samples from each subject (12
samples in total) were selected near Cmax and the elimination
phase in the pharmacokinetic profile.
The samples were considered stable; the percent differ-
ence should not be more than ±20% [16,17].
3. Results and discussion
3.1. Method development
To investigate the pharmacokinetics, tolerability and safety of
newer formulations, one should have appropriate analytical
method for its identification and quantification. Nowadays, rapid
and highly sensitive analytical techniques such as LC–MS are
most widely used in bio-analysis of drugs and metabolites.The
proposed LC–MS/MS method is developed with the aim to
quantify the methylprednisolone concentrations for a phar-
macokinetic and bioequivalence studies. Mass parameters were
tuned using tuning solution (100 ng/ml) of the analyte. Inten-
sity of the signals obtained in positive mode was much higher
than the negative mode. The compound parameters (CE, DP
and CXP) were suitably altered to obtain high intense and
consist product ion spectra of analyte. Additionally, satisfac-
tory response was obtained by changing the source dependent
parameters. A fast and efficient collision cell that can operate
at sufficient dwell to enable the acquisition of enough data
points across narrow LC peaks with a minimal loss in sensi-
tivity and no cross-talk. Hence, dwell time was set at 200 ms,
at which no cross talk was found. Protonated form of analyte
and the IS, [M+H]+ ion was the precursor ion in the Q1 spec-
trum and was used as the precursor ion to obtain Q3 product
ion spectra. The most sensitive mass transition was observed
from m/z 375.2 to 161.1 for analyte (Fig. 2A) and from m/z 431.3
to 323.3 for the IS (Fig. 2B). Date acquisition was performed with
Analyst Software™ (version 1.4.2) in the multiple reaction moni-
toring (MRM) mode.
After selecting the mass spectrometric conditions, chro-
matographic parameters such as column, mobile phase
composition and flow rate were critically assessed to have much
better quantification results. In general, acetonitrile and metha-
nol are trusted organic modifier intended for LC–MS analysis.
Hence, during method development both the solvents were
tested in combination with acidic buffers like ammonium
formate, ammonium acetate, formic acid and acetic acid. The
response obtained with methanol and 5 mM ammonium
formate as a mobile phase was sufficient for the quantifica-
tion of the analyte; but the peak shape was not good. Also, a
Fig. 2 – Product ion mass spectra of [M+H]+ of (A)
methylprednisolone and (B) budesonide (IS).
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variety of chromatographic columns like C8 and C18 of differ-
ent makes (Kromasil 100–5 C18, 100 × 4.6 mm, 5 μm; Zorbax SB
C18, 50 × 4.6, 5 μm; Discovery HS C18 50 mm × 4.6 mm, 5 μm;
Alltima HP C18 50 × 4.6, 3 μm; Zorbax XDB–phenyl 75 × 4.6, 3.5 μm;
Ace 3 C18 150 × 4.6, 3 μm; Hypurity advance 75 × 4.6, 5 μm) were
verified to achieve adequate retention time with short run time,
better separation from endogenous components, symmetric
peak shape and satisfactory response for the analyte. The best
chromatographic conditions were achieved with 10 mM am-
monium formate and acetonitrile (35:65, v/v) as a mobile phase
under isocratic conditions. Kromasil 100–5 C18, 100 × 4.6 mm,
5 μm column gave good peak shape and adequate response
even at LLOQ concentration (10.1 ng/ml) level for the analyte.
The mobile phase flow rate was set at 1.0 ml/min, which can
produce better acceptable chromatographic peak shape and
short run time of 2.8 min.
The reported procedures have employed PP [3], SPE [3,5–7,10]
and LLE [13] techniques for the extraction of the analyte form
plasma. But as the purpose was to develop a simple, rapid and
inexpensive method, LLE was tested with ethyl acetate, hexane,
tert–butyl methyl ether, dichloromethane and diethyl ether as
extraction solvents with/without acidic buffer addition to extract
methylprednisolone from the plasma samples. Also, LLE is
helpful in producing a spectroscopically clean sample and avoid-
ing the introduction of non-volatile materials onto the column
and MS system and also minimizing the experimental cost.
Poor recovery results were obtained with the ethyl acetate,
hexane, diethyl ether and dichloromethane. Promising results
were obtained with tert–butyl methyl ether, which gives clean
sample and yields the highest recovery for the analyte and the
IS. With or without the addition of extraction additives namely
ammonium formate, formic acid and ammonium acetate re-
sulted no difference in the recovery results of the analyte and
the IS. Hence, the extraction additives were not added to the
plasma samples.
A perfect internal standard should mimic the analyte during
ionization, chromatography and extraction. Ideally, a stable
labeled isotope drugs are preferably used in LC–MS/MS analy-
sis. But these compounds are expensive and/or not available
to serve as internal standard. So, at the initial stages of this
work, many compounds were investigated in order to find suit-
able IS; finally budesonide was selected, based on the
chromatographic elution, ionization and extraction effi-
ciency. Moreover, the current validation results encouraged its
selection as an internal standard.
3.2. Carryover test
Carryover evaluation is most important for desirable preci-
sion and accuracy of an analytical procedure. No significant
carryover was found in blank sample after injection ULOQ
sample with the working concentration of the IS indicating that
the proposed assay was not compromised due to carryover.
3.3. Selectivity
Selectivity of the proposed method was evaluated by analyz-
ing blank human plasma extract (Fig. 3A) and an extract spiked
only with the IS (Fig. 3B) obtained from six individual sources.
As shown in Fig. 3A, no significant direct interference in the
blank plasma traces was observed from endogenous compo-
nents at the retention time of the analyte and the IS. Similarly,
Fig. 3B shows the absence of direct interference from the IS
to the MRM channel of the analyte. Fig. 3C depicts a represen-
tative ion-chromatogram for the LLOQ sample (10.1 ng/ml).
Similarly, no interference was observed from commonly used
drugs such as paracetmol, nicotine, pantoprazole, ibuprofen,
caffeine, diphenhydramine, dicyclomine and pseudoephed-
rine (data not presented). Fig. 4 depicts a representative
chromatograms resulting from the analysis of subject blank
plasma sample along with the IS and 2.25 h subject plasma
sample after the single oral dose of a methylprednisolone 32 mg
tablet.
3.4. Sensitivity
The lowest measurable concentration with acceptable preci-
sion and accuracy for the proposed assay is 10.1 ng/ml, which
is set as a lowest limit of reliable quantification (LLOQ) for the
analyte. At this concentration the signal-to-noise ratio (S/N)
was found to be ≥10. The precision and accuracy at LLOQ con-
centration were found to be 3.28% and 107%, respectively.
3.5. Recovery
With the projected LLE method with TBME, good recoveries are
obtained for the analyte and the IS. The recovery results ob-
tained for analyte at low, middle and high QC concentrations
were 74.9%, 75.5% and 74.9%, respectively. The mean overall
recovery of methylprednisolone was 75.1 ± 0.36% with the pre-
cision range of 1.28–2.07% and the recovery of IS was 73.1%
with the precision range of 1.09–1.21%.
3.6. Matrix effect
Matrix effect assessment was done with the aim to check the
effect of different lots of plasma on the back calculated value
of QCs nominal concentration. The results found were well
within the acceptable limits as shown in Table 1. No signifi-
cant matrix effect was observed in all the six batches of human
plasma for the analyte at low and high quality control con-
centrations. Also, matrix factor was calculated at two different
concentration levels (LQC and HQC) in each plasma lot and the
results are presented in Table 1.
3.7. Linearity, precision and accuracy
The analyte showed good linearity in the concentration range
of 10.1–804 ng/ml. A total of five calibration curves were gen-
erated and correlation coefficient values were in the range of
0.9934–0.9978 for all the analytical runs generated during entire
course of validation. The precision and accuracy for the cali-
bration standards ranged from 1.66% to 6.92% and 96.55% to
107.16%, respectively.
The intra-day and inter-day precision and accuracy results
in plasma QC samples are summarized in Table 2. The preci-
sion (% CV) and accuracy values of methylprednisolone for intra-
and inter-day ranged 4.19–10.2% and 96.3–105%, and 5.28–
9.38% and 100–104%, respectively. The results revealed good
precision and accuracy.
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3.8. Dilution integrity
The real time subject plasma concentrations above the upper
concentration limit (1266 ng/ml) can be quantified by perform-
ing half (1:2) or quarter (1:4) dilution with screened human blank
plasma. The precision (% CV) and accuracy values of methyl-
prednisolone for dilution integrity of 1:2 was found to
be 1.22% and 94.1% and for dilution integrity of 1:4 dilution was
found to be 0.91% and 97.4%.
3.9. Long run evaluation
Long run evaluation experiment was conduct to determine
the size of a bio-analytical run during the study sample
Fig. 3 – Typical MRM chromatograms of methylprednisolone (left panel) and IS (right panel) in human blank plasma (A),
human blank plasma spiked with IS (B) and a LLOQ sample along with IS (C).
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analysis. A set of 195 plasma samples had been processed
and analyzed in a single run. 160 QCs out of 160 QCs of
long run evaluation and 24 QCs out of 24 QCs of freshly
spiked were within 15% of their respective nominal (theoreti-
cal) values.
The precision (%CV) and accuracy results for long run evalu-
ation QCs were ranged 2.21–2.68% and 98.9–100.2%, respectively.
Similarly, the precision (%CV) and accuracy results for freshly
spiked QCs were ranged 1.79–3.43% and 97.3–101%, respectively.
3.10. Method ruggedness
Bio-analytical method ruggedness was established with one
precision and accuracy (Batch–V) batch.The same samples were
processed by the different analyst using different sets of re-
agents and analyzed on the different instruments of the same
make by using different analytical columns (different batch no.).
The precision (%CV) and accuracy values for ruggedness batch
were ranged 1.79–3.43% and 97.1–101%, respectively.
Fig. 4 – MRM chromatograms resulting from the analysis of subject blank plasma sample (A) and 2.25 h subject plasma
sample (B), after the administration of a 32 mg oral single dose of methylprednisolone hydrochloride tablet. The sample
concentration was determined to be 312 ng/ml.
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3.11. Stability studies
A wide range stability experiments namely bench top stabil-
ity (15 h), repeated freeze–thaw cycles (4 cycles), auto-sampler
stability (65 h), reinjection stability (37 h), wet extract stabil-
ity (55 h at 2–8 °C) and long-term stability at −20 °C & −70 °C
for 56 days had been performed throughout validation. The
mean % nominal values were found to be within ±15% of the
predicted concentrations for the analyte at their LQC and HQC
levels and the precision (% CV) values were within 15% (Table 3).
All the stability study outcomes had been discovered for being
inside the specified limits over the total validation.
3.12. Pharmacokinetic results and incurred samples
reanalysis
The proposed assay procedure is successfully applied to a phar-
macokinetic study in healthy male South Indian subjects (n = 6).
The mean concentration (Cmax) in plasma (411 ± 44.2 ng/ml) for
methylprednisolone was attained at 2.39 ± 0.74 h (tmax) with a
Table 1 – Matrix effect assessment results of methylprednisolone in human plasma (n = 3).
Plasma lot LQC (30.2 ng/ml) HQC (709 ng/ml)
Concentration found
(mean ± SD; ng/ml)
%
Accuracy
IS normalized
MF
Concentration found
(mean ± SD; ng/ml)
%
Accuracy
IS normalized
MF
Lot 1 31.3 ± 1.83 104 0.98 731 ± 11.4 103 0.97
Lot 2 30.9 ± 2.00 102 0.94 718 ± 7.69 101 1.00
Lot 3 31.4 ± 0.99 104 0.93 737 ± 25.0 104 1.05
Lot 4 29.6 ± 2.09 97.9 0.92 738 ± 8.40 104 0.97
Lot 5 30.4 ± 1.85 101 0.94 726 ± 15.2 102 1.01
Lot 6 32.5 ± 0.93 108 0.94 729 ± 23.0 103 1.00
Table 2 – Precision and accuracy data for methylprednisolone.
Quality control Run Concentration
found
Precision (%) Accuracy
(%)
Intra-day variations (n = 12 at each concentration)
LLOQ 10.3 ± 0.80 7.76 102
LQC 29.1 ± 2.96 10.2 96.3
MQC1 88.3 ± 8.42 9.54 99.3
MQC2 424 ± 21.5 5.07 105
HQC 707 ± 29.6 4.19 99.8
Inter-day variations (n = 30 at each concentration)
LLOQ 10.2 ± 0.66 6.47 101
LQC 30.6 ± 2.87 9.38 101
MQC1 89.1 ± 6.45 7.24 100
MQC2 421 ± 22.2 5.28 104
HQC 722 ± 46.5 6.43 102
Nominal concentrations of LLOQ, LQC, MQC1, MQC2 and HQC are 10.1, 30.2, 88.9, 404 and 709 ng/ml, respectively.
Table 3 – Stability data for methylprednisolone in plasma (n = 6).
Stability test QC (spiked
concentration,
ng/ml)
Mean ± SD
(ng/ml)
Precision
(%)
Accuracy/
stability (%)
Bench top stability (15 h at room temperature) 30.2
709
32.8 ± 1.31
790 ± 33.2
3.99
4.21
109
111
Wet extract stability (at 2–8 °C for 5 h) 30.2
709
27.8 ± 0.55
674 ± 40.7
1.97
6.03
91.8
95.0
Autosampler stability (at 10 °C for 65 h) 30.2
709
27.8 ± 0.64
670 ± 7.15
2.31
1.07
91.9
94.5
Freeze–thaw stability (4 cycles) 30.2
709
28.5 ± 0.74
675 ± 19.3
2.61
2.86
94.2
95.2
Reinjection stability (37 h) 30.2
709
30.7 ± 0.80
703 ± 14.7
2.60
2.10
102
99.1
Long-term Stability (at −20 °C for 56 days) 30.2
709
28.1 ± 0.48
686 ± 13.2
1.72
1.92
92.9
96.8
Long-term Stability (at −70 °C for 56 days) 30.2
709
31.3 ± 1.10
663 ± 13.0
3.51
1.96
104
93.5
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half-life (t1/2) of 3.68 ± 0.49 h. The area under the plasma
concentration–time curve from time zero to last measurable
time point (AUC0–t) and area under the plasma concentration
time curve from time zero to infinity time point (AUC0–inf) for
methylprednisolone were 2644 ± 464 and 2697 ± 485 ng h/ml,
respectively. The mean plasma concentration vs time profile
of methylprednisolone is shown in Fig. 5. The study data ob-
tained are authenticated by means of ISR and the obtained
results are presented in Table 4. The results demonstrated that
the excellent reproducibility of the proposed method.
4. Conclusions
The LC–MS/MS assay reported here is simple, rapid, specific
and sensitive for quantification of methylprednisolone in
human plasma and is fully validated according to commonly
acceptable US FDA and EMEA guidelines. The simple LLE ex-
traction with TBME extraction method gave consistent and
reproducible recoveries for the analyte from the human plasma.
The method provided good linearity.The stability of the analyte
in plasma and in aqueous samples under different condi-
tions has been extensively evaluated. A sample turnover rate
of less than 2.8 min makes it an attractive procedure in high-
throughput bioanalysis of methylprednisolone.The method was
found to be reliable and reproducible to support pharmacoki-
netic study in humans. From the results of all the validation
parameters, we can conclude that the developed method can
be useful for bioavailability and bioequivalence (BA/BE) studies
and routine therapeutic drug monitoring with the desired pre-
cision and accuracy.
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